Kidney International Reports最新文献

英文中文

WCN25-628 RISK FACTORS FOR ACUTE KIDNEY INJURY AND THE PROGRESSION INTO ACUTE KIDNEY DISEASE IN HOSPITALISED HEART FAILURE PATIENTS: A SINGLE-CENTRE, RETROSPECTIVE STUDY

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2025-02-01 DOI: 10.1016/j.ekir.2024.11.109

Jia Qi Low ∗ , Soo Ying Yew , Loch Alexander , Ruhana Che Yusof , Soo Kun Lim

引用次数: 0

WCN25-625 ASSESSING RENAL FUNCTION IN PATIENTS UNDERGOING TARGETED CANCER THERAPIES: THE ROLE OF CYSTATIN C IN PALBOCICLIB-INDUCED SERUM CREATININE ELEVATION

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2025-02-01 DOI: 10.1016/j.ekir.2024.11.108

Kais Harzallah ∗

引用次数: 0

WCN25-4034 ANCA mediated glomerular lesion on top of diabetic nephropathy, a case report

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2025-02-01 DOI: 10.1016/j.ekir.2024.11.163

Sk Md Jaynul Islam ∗ , Meheruba Alam Anannya

引用次数: 0

WCN25-3657 TACROLIMUS INDUCED HYPONATREMIA TREATED WITH FLUDROCORTISONE

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2025-02-01 DOI: 10.1016/j.ekir.2024.11.083

Shrikant Deshmukh ∗ , Vajed Mogal

引用次数: 0

IFT140-related ADPKD

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2025-02-01 DOI: 10.1016/j.ekir.2024.12.008

Martina Catania , Giulia Mancassola , Liliana Italia De Rosa , Kristiana Kola , Gino Pepe , Paolo Manunta , Giuseppe Vezzoli , Paola Carrera , Maria Teresa Sciarrone Alibrandi

引用次数: 0

Reintegration Into the Workforce After Kidney Transplantation Based on Urbanization Status in Switzerland

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2025-02-01 DOI: 10.1016/j.ekir.2024.10.029

Federica Bocchi , Selina Müller , Isabelle Binet , Dela Golshayan , Fadi Haidar , Thomas Müller , Stefan Schaub , Aurelia Schnyder , Daniel Sidler , Federico Storni

Introduction

Most of Switzerland’s population and employment opportunities are concentrated in urban areas. Although kidney transplantation (KT) is the preferred therapy for eligible candidates, individuals in rural areas face challenges accessing specialized medical services due to longer travel distances. Limited understanding exists regarding patients' perspectives on returning to work after KT and whether this correlates with their urbanization status, potentially influencing outcomes.

Methods

Retrospective, nationwide (Swiss Transplant Cohort Study [STCS]) study, from May 2008 to 2020, including 1926 patients aged 18 to 60 years who underwent KT. We investigated the self-reported work reintegration at 1, 3, and 5 years after the KT, the recipient and allograft survival, and the allograft function at 12 months, contingent on urbanization status (urban, suburban, rural).

Results

The return rate of sufficiently filled-in questionnaires was 81% (1053 participants). Urban recipients were younger, had longer dialysis time before KT, and had less living donor KT. At baseline, the level of education, as well as the workforce defined as work capacity > 50%, were lower in urban areas (37% urban, 39% suburban, and 47% rural). Regression analysis revealed significantly higher odds ratio for employment 1 year post-KT among patients residing in rural and suburban areas (odds ratio: 1.31 [confidence interval: 1.04–1.65] and 1.52 [confidence interval: 1.16–1.98], respectively) compared to patients from urban regions. Stratified according to urbanization environment, recipient and allograft survival were comparable across groups.

Conclusion

Patient and graft outcomes were favorable, with improved work reintegration observed at the 1-year mark post-KT for recipients from rural backgrounds compared to those from suburban and urban areas.

{"title":"Reintegration Into the Workforce After Kidney Transplantation Based on Urbanization Status in Switzerland","authors":"Federica Bocchi , Selina Müller , Isabelle Binet , Dela Golshayan , Fadi Haidar , Thomas Müller , Stefan Schaub , Aurelia Schnyder , Daniel Sidler , Federico Storni","doi":"10.1016/j.ekir.2024.10.029","DOIUrl":"10.1016/j.ekir.2024.10.029","url":null,"abstract":"<div><h3>Introduction</h3><div>Most of Switzerland’s population and employment opportunities are concentrated in urban areas. Although kidney transplantation (KT) is the preferred therapy for eligible candidates, individuals in rural areas face challenges accessing specialized medical services due to longer travel distances. Limited understanding exists regarding patients' perspectives on returning to work after KT and whether this correlates with their urbanization status, potentially influencing outcomes.</div></div><div><h3>Methods</h3><div>Retrospective, nationwide (Swiss Transplant Cohort Study [STCS]) study, from May 2008 to 2020, including 1926 patients aged 18 to 60 years who underwent KT. We investigated the self-reported work reintegration at 1, 3, and 5 years after the KT, the recipient and allograft survival, and the allograft function at 12 months, contingent on urbanization status (urban, suburban, rural).</div></div><div><h3>Results</h3><div>The return rate of sufficiently filled-in questionnaires was 81% (1053 participants). Urban recipients were younger, had longer dialysis time before KT, and had less living donor KT. At baseline, the level of education, as well as the workforce defined as work capacity > 50%, were lower in urban areas (37% urban, 39% suburban, and 47% rural). Regression analysis revealed significantly higher odds ratio for employment 1 year post-KT among patients residing in rural and suburban areas (odds ratio: 1.31 [confidence interval: 1.04–1.65] and 1.52 [confidence interval: 1.16–1.98], respectively) compared to patients from urban regions. Stratified according to urbanization environment, recipient and allograft survival were comparable across groups.</div></div><div><h3>Conclusion</h3><div>Patient and graft outcomes were favorable, with improved work reintegration observed at the 1-year mark post-KT for recipients from rural backgrounds compared to those from suburban and urban areas.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 2","pages":"Pages 565-573"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143160028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel Hepatitis B Virus Reactivation Monitoring Strategies for Kidney Transplant Patients

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2025-02-01 DOI: 10.1016/j.ekir.2024.10.031

Hsien-Chung Yu , Chien-Liang Chen , Kung-Hung Lin , Chih-Yang Hsu , Po-Tsang Lee

引用次数: 0

“Normal” Glomerular Score Correlates With Outcomes in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis With Glomerulonephritis

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2025-02-01 DOI: 10.1016/j.ekir.2024.11.019

Marta Casal Moura , Fernando C. Fervenza , Ulrich Specks , Sanjeev Sethi

引用次数: 0

Identification and Prioritization of Canadian Society of Nephrology Clinical Practice Guideline Topics

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2025-02-01 DOI: 10.1016/j.ekir.2024.11.006

Tyrone G. Harrison , Melissa Schorr , Brigitte H. Baragar , Gregory L. Hundemer , Krista S. Ryz , Nancy Verdin , Tania Woodlock , David A. Clark , Reem A. Mustafa , Anna Mathew , Canadian Society of Nephrology Clinical Practice Guidelines Committee

Introduction

Nephrology clinical practice guideline topics are routinely determined by clinicians and researchers, without extensive engagement of people with lived experience (PWLE) of kidney disease and their caregivers. The Canadian Society of Nephrology (CSN) Clinical Practice Guidelines Committee (CPGC) completed this modified Delphi study to incorporate diverse stakeholder perspectives in identifying and prioritizing future guideline topics.

Methods

We recruited nephrology clinicians, researchers, PWLE of kidney disease or their caregivers for this study. We collated literature-derived guideline topics from international and national guideline organizations that had relevance to nephrology, in addition to suggestions from participants. Consenting participants were taken through a 3 round Delphi survey process, where items were ranked on a 9-point Likert scale in terms of their importance. Based on predetermined consensus criteria, items were accepted as a priority or excluded from further consideration. We ranked the prioritized topics and compared the median ranking between clinicians or researchers and PWLE in the round where consensus was reached.

Results

Of the 85 consenting participants, 76 to 78 completed each Delphi round. From the initial list of 100 topics for consideration, 12 were priorities. All stakeholder groups felt it was important for PWLE to be included in topic prioritization and guideline development. The 3 most highly prioritized topics were de novo guidelines on novel therapeutics to prevent or slow progression of chronic kidney disease (CKD), recommendations for primary care, and patient-oriented guidelines on diet and exercise in kidney disease. There were no statistical differences in the median ranking between stakeholder groups (P > 0.05).

Conclusion

This study will inform the future nephrology guidelines and commentaries developed by the CSN.

{"title":"Identification and Prioritization of Canadian Society of Nephrology Clinical Practice Guideline Topics","authors":"Tyrone G. Harrison , Melissa Schorr , Brigitte H. Baragar , Gregory L. Hundemer , Krista S. Ryz , Nancy Verdin , Tania Woodlock , David A. Clark , Reem A. Mustafa , Anna Mathew , Canadian Society of Nephrology Clinical Practice Guidelines Committee","doi":"10.1016/j.ekir.2024.11.006","DOIUrl":"10.1016/j.ekir.2024.11.006","url":null,"abstract":"<div><h3>Introduction</h3><div>Nephrology clinical practice guideline topics are routinely determined by clinicians and researchers, without extensive engagement of people with lived experience (PWLE) of kidney disease and their caregivers. The Canadian Society of Nephrology (CSN) Clinical Practice Guidelines Committee (CPGC) completed this modified Delphi study to incorporate diverse stakeholder perspectives in identifying and prioritizing future guideline topics.</div></div><div><h3>Methods</h3><div>We recruited nephrology clinicians, researchers, PWLE of kidney disease or their caregivers for this study. We collated literature-derived guideline topics from international and national guideline organizations that had relevance to nephrology, in addition to suggestions from participants. Consenting participants were taken through a 3 round Delphi survey process, where items were ranked on a 9-point Likert scale in terms of their importance. Based on predetermined consensus criteria, items were accepted as a priority or excluded from further consideration. We ranked the prioritized topics and compared the median ranking between clinicians or researchers and PWLE in the round where consensus was reached.</div></div><div><h3>Results</h3><div>Of the 85 consenting participants, 76 to 78 completed each Delphi round. From the initial list of 100 topics for consideration, 12 were priorities. All stakeholder groups felt it was important for PWLE to be included in topic prioritization and guideline development. The 3 most highly prioritized topics were <em>de novo</em> guidelines on novel therapeutics to prevent or slow progression of chronic kidney disease (CKD), recommendations for primary care, and patient-oriented guidelines on diet and exercise in kidney disease. There were no statistical differences in the median ranking between stakeholder groups (<em>P</em> > 0.05).</div></div><div><h3>Conclusion</h3><div>This study will inform the future nephrology guidelines and commentaries developed by the CSN.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 2","pages":"Pages 396-405"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143161291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addition of a Loop Diuretic to Norepinephrine During Treatment of Hepatorenal Syndrome Type 1

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2025-02-01 DOI: 10.1016/j.ekir.2024.11.013

Juan Carlos Q. Velez , Terrance J. Wickman , Kasra Tayebi , Muner M.B. Mohamed , Adil Yousuf , Swetha R. Kanduri , Ivo Lukitsch , Derek Vonderhaar , Karthik Kovvuru , Cathy Wentowski

Introduction

Diuretics are commonly discontinued in patients with cirrhosis with acute kidney injury (AKI) because they are presumed to trigger hepatorenal syndrome type 1 (HRS-1). We hypothesized that if HRS-1 is adequately treated with a vasoconstrictor (mean arterial pressure [MAP] effectively increased), diuretics are safe and effective.

Methods

Records of hospitalized patients with cirrhosis who received i.v. furosemide while receiving i.v. norepinephrine as a vasoconstrictor to treat HRS-1 were examined. We assessed change in urine output (UOP), trajectory of serum creatinine (sCr), and impact of portopulmonary hypertension (PoPHTN) on the therapeutic response.

Results

Twenty-six patients with HRS-1 received i.v. furosemide (median: 2 days, 160 mg boluses every 6–24 hours) added to i.v. norepinephrine. Median age was 51 years; 91% were of White race, 36% were women, and median model for end-stage liver disease score was 32. The median initial sCr was 4.0 mg/dl. Before treatment, median UOP was 358 ml/d. Norepinephrine alone led to a median increase in UOP to 850 ml/d. Addition of furosemide to norepinephrine induced a subsequent increase in median UOP to 2072 ml/d (P < 0.0001), which was not observed in a control group (n = 22) who did not receive furosemide. Nineteen patients (73%) treated with norepinephrine plus furosemide (median MAP increase, 16 mm Hg) either maintained or improved their sCr trajectory. The magnitude of norepinephrine-induced increase in MAP correlated with the norepinephrine plus furosemide-induced UOP (r = 0.67, P = 0.0002), and the correlation coefficient was numerically stronger among those with PoPHTN.

Conclusion

In patients with HRS-1 who are adequately treated with norepinephrine and achieved an optimal MAP increment, addition of i.v. furosemide enhances diuresis without negatively affecting renal recovery.

{"title":"Addition of a Loop Diuretic to Norepinephrine During Treatment of Hepatorenal Syndrome Type 1","authors":"Juan Carlos Q. Velez , Terrance J. Wickman , Kasra Tayebi , Muner M.B. Mohamed , Adil Yousuf , Swetha R. Kanduri , Ivo Lukitsch , Derek Vonderhaar , Karthik Kovvuru , Cathy Wentowski","doi":"10.1016/j.ekir.2024.11.013","DOIUrl":"10.1016/j.ekir.2024.11.013","url":null,"abstract":"<div><h3>Introduction</h3><div>Diuretics are commonly discontinued in patients with cirrhosis with acute kidney injury (AKI) because they are presumed to trigger hepatorenal syndrome type 1 (HRS-1). We hypothesized that if HRS-1 is adequately treated with a vasoconstrictor (mean arterial pressure [MAP] effectively increased), diuretics are safe and effective.</div></div><div><h3>Methods</h3><div>Records of hospitalized patients with cirrhosis who received i.v. furosemide while receiving i.v. norepinephrine as a vasoconstrictor to treat HRS-1 were examined. We assessed change in urine output (UOP), trajectory of serum creatinine (sCr), and impact of portopulmonary hypertension (PoPHTN) on the therapeutic response.</div></div><div><h3>Results</h3><div>Twenty-six patients with HRS-1 received i.v. furosemide (median: 2 days, 160 mg boluses every 6–24 hours) added to i.v. norepinephrine. Median age was 51 years; 91% were of White race, 36% were women, and median model for end-stage liver disease score was 32. The median initial sCr was 4.0 mg/dl. Before treatment, median UOP was 358 ml/d. Norepinephrine alone led to a median increase in UOP to 850 ml/d. Addition of furosemide to norepinephrine induced a subsequent increase in median UOP to 2072 ml/d (<em>P</em> < 0.0001), which was not observed in a control group (<em>n</em> = 22) who did not receive furosemide. Nineteen patients (73%) treated with norepinephrine plus furosemide (median MAP increase, 16 mm Hg) either maintained or improved their sCr trajectory. The magnitude of norepinephrine-induced increase in MAP correlated with the norepinephrine plus furosemide-induced UOP (<em>r</em> = 0.67, <em>P</em> = 0.0002), and the correlation coefficient was numerically stronger among those with PoPHTN.</div></div><div><h3>Conclusion</h3><div>In patients with HRS-1 who are adequately treated with norepinephrine and achieved an optimal MAP increment, addition of i.v. furosemide enhances diuresis without negatively affecting renal recovery.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 2","pages":"Pages 466-474"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143161354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Kidney International Reports

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀